These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35946486)

  • 1. Mineral and bone disorder and longterm survival in a chronic kidney disease grade 3b-4cohort.
    Rios P; Silvariño R; Sola L; Ferreiro A; Lamadrid V; Fajardo L; Gadola L
    Ren Fail; 2022 Dec; 44(1):1356-1367. PubMed ID: 35946486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort.
    Reimer KC; Nadal J; Meiselbach H; Schmid M; Schultheiss UT; Kotsis F; Stockmann H; Friedrich N; Nauck M; Krane V; Eckardt KU; Schneider MP; Kramann R; Floege J; Saritas T;
    Bone Res; 2023 Oct; 11(1):52. PubMed ID: 37857629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early renal impairment affects hormonal regulators of calcium and bone metabolism and Wnt signalling and the response to vitamin D supplementation in healthy older adults.
    Christodoulou M; Aspray TJ; Piec I; Washbourne C; Tang JCY; Fraser WD; Schoenmakers I;
    J Steroid Biochem Mol Biol; 2023 May; 229():106267. PubMed ID: 36739953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?
    Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP
    J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of chronic kidney disease related-mineral bone disorders in newly diagnosed advanced predialysis diabetic kidney disease patients: A hospital based cross-sectional study.
    Ray S; Beatrice AM; Ghosh A; Pramanik S; Bhattacharjee R; Ghosh S; Raychaudhury A; Mukhopadhyay S; Chowdhury S
    Diabetes Metab Syndr; 2017 Dec; 11 Suppl 2():S931-S937. PubMed ID: 28728874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients.
    Lee SA; Lee MJ; Ryu GW; Jhee JH; Kim HW; Park S; Jung SY; Oh HJ; Park JT; Han SH; Kang SW; Yoo TH
    Osteoporos Int; 2016 Sep; 27(9):2717-2726. PubMed ID: 27216997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.
    Molina P; Molina MD; Pallardó LM; Torralba J; Escudero V; Álvarez L; Peris A; Sánchez-Pérez P; González-Rico M; Puchades MJ; Fernández-Nájera JE; Giménez-Civera E; D'Marco L; Carrero JJ; Górriz JL
    J Nephrol; 2021 Aug; 34(4):1189-1199. PubMed ID: 33394344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population.
    Ngai M; Lin V; Wong HC; Vathsala A; How P
    Clin Nephrol; 2014 Oct; 82(4):231-9. PubMed ID: 25161115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circulating bone turnover markers and their relationships in hemodialysis patients with vitamin D deficiency].
    Kulicki P; Żebrowski P; Sokalski A; Klatko W; Birecka M; Mieczkowski M; Niemczyk S; Małyszko J; Matuszkiewicz-Rowińska J
    Wiad Lek; 2019; 72(11 cz 2):2202-2209. PubMed ID: 31860837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
    J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of FGF-23 With Biochemical Markers and Bone Density in Chronic Kidney Disease-Bone Mineral Density Disorder.
    Hussain I; Tandi R; Singh G; Kaur G; Abhishek ; Dodda S; Patel D; Natarajan B; Maram T; Kedia A; Vempati R; Sahu S; Choubey U
    Cureus; 2023 Jan; 15(1):e33879. PubMed ID: 36812096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
    Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA
    Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.
    Floege J; Kim J; Ireland E; Chazot C; Drueke T; de Francisco A; Kronenberg F; Marcelli D; Passlick-Deetjen J; Schernthaner G; Fouqueray B; Wheeler DC;
    Nephrol Dial Transplant; 2011 Jun; 26(6):1948-55. PubMed ID: 20466670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH; Bergrem H; Hartmann A; Godang K; Gøransson LG
    BMC Nephrol; 2012 Jun; 13():49. PubMed ID: 22742720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate.
    Muntner P; Jones TM; Hyre AD; Melamed ML; Alper A; Raggi P; Leonard MB
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):186-94. PubMed ID: 19019998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.